Zhiyun Niu

Ms. Zhiyun Niu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2026 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
MHMingxin Hu
Mingxin Hu
CHChaoxing He
Chaoxing He
JHJintao Hao
Jintao Hao
NQNannan Qi
Nannan Qi
KHKe He
Ke He
ZNZhiyun Niu
Zhiyun Niu
Leukemia is a highly heterogeneous and aggressive hematological malignancy. Current therapeutic approaches (e.g. chemotherapy, radiotherapy, small-molecule

25 July 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
YZYuxin Zhang
Yuxin Zhang
YZYingkun Zhang
Yingkun Zhang
AYAizhen Yang
Aizhen Yang
YZYabei Zuo
Yabei Zuo
XYXiaofeng Yan
Xiaofeng Yan
JZJingyu Zhang
Jingyu Zhang
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, yet the contribution of specific VWF domains to its pathogenesis remains incompletely understood. In particular, the role of the D4 domain in VWF secretion, intracellular maturation, and multimer formation has not been fully elucidated. Here, we investigated the functional impact of a heterozygous p.Cys2163Tyr variant located in the D4 domain, identified in a patient with a severe bleeding phenotype, using clinical evaluation, genetic analysis, family studies, and in vitro expression assays. Laboratory testing revealed markedly reduced VWF:Ag (6.8 IU/dL), VWF:GPIbR (0.1 IU/dL), and FVIII:C levels, indicating a severe VWD phenotype in the proband. Plasma VWF multimer analysis showed a markedly reduced overall VWF signal with an almost complete absence of high-molecular-weight multimers, supporting classification of the phenotype as severe type 2A VWD. The heterozygous c.6488G>A (p.Cys2163Tyr) variant was also present in asymptomatic family members, indicating incomplete segregation with the severe phenotype and suggesting that this variant alone is insufficient to explain the proband’s disease severity. Notably, the proband’s mother exhibited mildly reduced VWF levels in the absence of this variant, suggesting the possible contribution of an additional unidentified defect or modifier affecting the maternal allele. In vitro expression demonstrated preserved intracellular VWF antigen, markedly reduced secretion of mutant VWF, and loss of high-molecular-weight VWF multimers. Together, these findings indicate that VWF p.Cys2163Tyr is a functionally deleterious variant that markedly impairs VWF secretion and high-molecular-weight multimer formation in vitro. However, the incomplete segregation observed in the family suggests that this heterozygous variant alone may not fully account for the proband’s severe type 2A VWD phenotype.

4 May 2026 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
YZYabei Zuo
Yabei Zuo
LGLi Geng
Li Geng
YGYujie Guo
Yujie Guo
DZDaitianchang Zhao
Daitianchang Zhao
NQNannan Qi
Nannan Qi
ZNZhiyun Niu
Zhiyun Niu


1 October 2026 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
NQNannan Qi
Nannan Qi
JHJintao Hao
Jintao Hao
YLYilin Li
Yilin Li
YZYabei Zuo
Yabei Zuo
YWYan Wang
Yan Wang
ZNZhiyun Niu
Zhiyun Niu
TP53-mutated acute myeloid leukemia (TP53-mut AML) resists venetoclax-based therapy largely due to loss of p53-mediated mitochondrial priming. We developed